Skip to content

Immunotherapy for pycnodysostosis

Immunotherapy for pycnodysostosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNC-10000876
Enrollment
Unknown
Registered
2010-05-26
Start date
2009-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pycnodysostosis

Interventions

Group A:600 mg of Total Glucosides of White Peony Capsules (State Drug Approval No. H20055058, produced by Lansen Pharmaceutical Holdings., China) were taken three times per day for one month
10 mg of Thymopeptide Eneric-Coated Capsules (State Drug Approval No. 19991132, Shanghai Baolong Pharmaceutical Holdings, China) were taken three times per day for one month
saline rinse with local iodophors treatment weekly till the wound was healed.

Sponsors

School of Stomatology, The Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: individual with clinical features of pycnodysostosis and mutation of CTSK gene

Exclusion criteria

Exclusion criteria: No Restriction

Design outcomes

Primary

MeasureTime frame
serum IL-17A (pg/mL);Ratio(CD3+ CD4+/ CD3+ CD8+);exposed surface of alveolar bone;Swelling and pain in infraorbital region;

Countries

China

Contacts

Public ContactXiaohong Duan
xhduan@fmmu.edu.cn+86 29 84776169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 5, 2026